Drug intelligence / Profile preview

GS301

Development stage: Preclinical
Lead developer: Jiangsu Genscend Biopharmaceutical
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravitreal

Overview

GS301 is a bispecific monoclonal antibody biosimilar of faricimab (Vabysmo) being developed by Jiangsu Genscend Biopharmaceutical. It is designed to target both vascular endothelial growth factor A (VEGF-A) and angiopoietin-2 (Ang2) to inhibit dual pathways involved in retinal vascular diseases. The candidate is currently in preclinical and IND-enabling development for ophthalmic indications, such as retinal diseases, with an Investigational New Drug (IND) application projected for late 2026.

Other names: Faricimab biosimilarFaricimab biosimilar (Genscend Biopharmaceutical)Faricimab biosimilar (Jiangsu Genscend Biopharmaceutical)Faricimab biosimilar (Jiangsu Genscend Biopharmaceutical Co., Ltd)

Targets

ANGPT2 (Angiopoietin-2)VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on GS301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GS301.

Explore the full profile